After her own multiple sclerosis diagnosis 10 years ago, Parisa Khosravi became an advocate and a clinician for an autoimmune ...

What do federal funding cuts mean for MS researchers and those living with the disease? Then, should you kiss your dentist ...

The patent comes months after Immunic Therapeutics announced CALLIPER study results, which tested vidofludimus calcium in ...

The first signs of multiple sclerosis (MS) may appear much earlier than most doctors once believed. A new study suggests that ...

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Ocrevus rapidly depletes immune B-cells in people with MS, but ongoing treatment also leads to changes in immune T-cells, a ...

A previously "hidden" subtype of Multiple Sclerosis (MS)—a condition that affects the brain and spinal cord—has been ...

Great Place To Work® and Fortune magazine have selected the International Multiple Sclerosis Management Practice (IMSMP) for the 2025 Fortune Best Workplaces in Health Care™ List. This recognition ...

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

Nearly 80% of neurologists prescribing multiple sclerosis drugs received $164M from pharma companies, and a new BMJ Open ...

King's College London and Imperial College London, in collaboration with the UK MS Register, report a prevalent multiple ...

Background Benign multiple sclerosis (MS), characterised by minimal disability despite long disease duration, remains poorly understood in terms of its determinants and prognostic implications. While ...